Zane Giffen, MD
Urology · Ravenna, OHNPI 1841653029
Payments from drug & device makers
Across 256 payments — averaging $38.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$2K
- Teleflex LLC$2K
- Procept Biorobotics Corporation$1K
- Axonics, Inc.$954
- Sumitomo Pharma America, Inc.$630
- Medtronic$384
- plus $2K from 27 others
What the payments were for
- Travel & lodging$3,19633%
- Food & beverage$6,57667%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 25 | $2,287 |
| Teleflex LLC | 12 | $1,649 |
| Procept Biorobotics Corporation | 5 | $1,442 |
| Axonics, Inc. | 41 | $954 |
| Sumitomo Pharma America, Inc. | 31 | $630 |
| Medtronic | 11 | $384 |
| Convatec Inc. | 8 | $302 |
| Endo Pharmaceuticals Inc. | 25 | $280 |
| Urovant Sciences Inc | 22 | $257 |
| Astellas Pharma US Inc | 14 | $223 |
| AbbVie | 8 | $185 |
| Antares Pharma, Inc. | 7 | $129 |
| C. R. Bard, Inc. & Subsidiaries | 1 | $119 |
| Myovant Sciences Inc. | 7 | $95 |
| Progenics Pharmaceuticals, Inc. | 5 | $92 |
| Halozyme Inc | 4 | $82 |
| Laborie Medical Technologies Corp. | 4 | $79 |
| Rochester Medical Corporation | 3 | $72 |
| Olympus America Inc. | 3 | $71 |
| Urogen Pharma, Inc. | 3 | $62 |
| Caldera Medical, Inc | 1 | $56 |
| Dendreon Pharmaceuticals LLC | 2 | $51 |
| Johnson & Johnson | 3 | $50 |
| Sanofi | 1 | $32 |
| Clarus Therapeutics Inc. | 2 | $31 |
| Novartis | 1 | $26 |
| Calyxo, Inc. | 1 | $24 |
| Tolmar, Inc. | 1 | $20 |
| Verity Pharmaceuticals Inc. | 1 | $20 |
| Coloplast | 1 | $19 |
| Photocure Inc | 1 | $18 |
| Travere Therapeutics, Inc. | 1 | $16 |
| SRS Medical Systems, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AquaBeam Robotic System$1,410
- UroLift$1,353
- LithoVue$274
- INTERSTIM$229
- LITHOCLAST$175
- FLEXIVA$161
- GEMTESA$123
- Lumenis Pulse 120H$123
- Bard Urinary Drainage Bag$119
- UroLift System$113
- Axonics$106
How this compares
$9,772 in reported general payments places this provider in the 75th percentile of 485 urology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 62 | $42,323 |
| OrgovyxRelugolix | 15 | $41,629 |
| MyrbetriqMirabegron | 61 | $34,860 |
| Tamsulosin Hcl | 270 | $2,444 |
| Potassium Citrate ErPotassium Citrate | 11 | $1,730 |
| Finasteride | 73 | $1,178 |
| Oxybutynin Chloride ErOxybutynin Chloride | 43 | $938 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 44 | $899 |
| Estradiol | 14 | $814 |
| Testosterone Cypionate | 17 | $719 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 36 | $393 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 19 | $325 |
| Cefadroxil | 72 | $290 |
| Trospium Chloride | 11 | $280 |
| Trimethoprim | 13 | $278 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa, Orgovyx | $630 | $83,95277 claims |
| Astellas Pharma US IncMyrbetriq | $223 | $34,86061 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 485 urology providers in Ohio.
Other urology in Ravenna
- Marc PliskinCincinnati$20.8M
- Lawrence GervasiMiddleburg Heights$4.7M
- Martin FritzhandCincinnati$4.6M
- Kamal PoharCincinnati$3.4M
- Eric SingerColumbus$2.1M
- Benjamin MartinGahanna$1.1M
- Howard GoldmanCleveland$747K
- Jihad KaoukCleveland$696K
- Raymond RackleyCleveland$695K
- Sandip VasavadaCleveland$512K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.